Molnupiravir
Molnupiravir is an oral antiviral considered early in COVID-19 for selected adults at higher risk of severe illness. It is not a general treatment for any viral infection and is not a substitute for urgent assessment when symptoms are severe.
Key points
- Eligibility depends on confirmed or strongly suspected COVID-19, symptom timing, risk factors and whether more suitable options are available.
- Pregnancy and reproductive considerations require review before treatment because of potential effects on a developing fetus.
- Worsening breathlessness, chest pain, confusion or blue-grey lips or skin needs urgent medical care.
Listings are for comparison only. Suitability and supply depend on clinician and pharmacy checks, stock, destination rules and prescription requirements.
What Molnupiravir is used for
Molnupiravir may be considered for selected adults with mild to moderate COVID-19 who are at increased risk of progressing to severe illness. It is not used to prevent COVID-19 or to replace hospital treatment when severe disease is present.
How it works
After activation in the body, molnupiravir introduces copying errors into the virus’s genetic material, reducing its ability to replicate. Treatment is time-sensitive because viral replication is greatest early in illness.
Important safety checks
Pregnancy status, the possibility of pregnancy, reproductive plans, age, symptom onset and other treatment options need review. Do not share leftover capsules or use them for a later respiratory illness without a new assessment.
When to seek urgent care
Seek urgent help for worsening breathlessness, persistent chest pain, fainting, new confusion, inability to stay awake, blue-grey lips or skin, coughing blood or signs of a severe allergic reaction.